PYC Therapeutics (ASX:PYC) ROE % Adjusted to Book Value: -4.39% (As of Dec. 2025)


ASX:PYC PYC Therapeutics Ltd ASX:PYC
35 GF Score
Price A$1.54
! 1 Warning Sign
View Full Analysis

What is PYC Therapeutics ROE % Adjusted to Book Value?

PYC Therapeutics ASX:PYC 35 ROE % Adjusted to Book Value is -4.39% as of Dec. 2025. GuruFocus rates ASX:PYC with a GF Score™ of 35/100. The stock has 1 warning sign investors should review.

PYC Therapeutics's ROE % for the quarter that ended in Dec. 2025 was -28.83%. PYC Therapeutics's PB Ratio for the quarter that ended in Dec. 2025 was 6.57. PYC Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 was -4.39%.

PYC Therapeutics ROE % Adjusted to Book Value Related Terms

PYC Therapeutics ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for PYC Therapeutics's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PYC Therapeutics ROE % Adjusted to Book Value Chart

PYC Therapeutics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.72 -5.76 -9.86 -10.04 -9.04

PYC Therapeutics Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -7.64 -11.82 -6.75 -9.88 -4.39

ASX:PYC vs VRTX, REGN, ALNY: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, PYC Therapeutics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PYC Therapeutics ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PYC Therapeutics's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where PYC Therapeutics's ROE % Adjusted to Book Value falls into.


ASX:PYC
35GF Score
PYC Therapeutics Ltd ASX:PYC
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PYC Therapeutics ROE % Adjusted to Book Value Calculation

PYC Therapeutics's ROE % Adjusted to Book Value for the fiscal year that ended in Jun. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-40.23% / 4.45
=-9.04%

PYC Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-28.83% / 6.57
=-4.39%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of -4.39% mean?
PYC Therapeutics (ASX:PYC) has a ROE % Adjusted to Book Value of -4.39% as of Dec. 2025. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on PYC Therapeutics and its competitors.
Is PYC Therapeutics' ROE % Adjusted to Book Value too high?
PYC Therapeutics' current ROE % Adjusted to Book Value is -4.39%. Overall, PYC Therapeutics has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does PYC Therapeutics' ROE % Adjusted to Book Value compare to VRTX and REGN?
PYC Therapeutics' ROE % Adjusted to Book Value of -4.39% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on PYC Therapeutics and its competitors. PYC Therapeutics's current ROE % Adjusted to Book Value is -4.39%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PYC Therapeutics stock overvalued right now?
PYC Therapeutics (ASX:PYC) has a current ROE % Adjusted to Book Value of -4.39%. The current ROE % Adjusted to Book Value is -4.39%. PYC Therapeutics' overall GF Score™ is 35/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For PYC Therapeutics (ASX:PYC), the current ROE % Adjusted to Book Value is -4.39% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PYC Therapeutics Business Description

Other Exchanges PYCXF:USA
Address 6 Verdun Street, Harry Perkins Institute of Medical Research, Nedlands, Perth, WA, AUS, 6009
PYC Therapeutics Ltd is an RNA therapeutics drug development company, leveraging a proprietary delivery platform to solve the challenges in RNA therapeutics - safe and effective delivery of the drug inside the cell. The company's principal business activity is of of drug development and progressing the company's drug pipeline through preclinical and clinical development. Geographically, it operates only in Australia.
35GF Score

Get the complete analysis for ASX:PYC

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$1.54
Price